News & Resources


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.09 (2.88%)
Jun 26, 2017 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
05/16/17Orexigen Announces Activities at European Congress on Obesity 2017Printer Friendly Version
05/09/17Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017Printer Friendly Version
05/02/17Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare ConferencePrinter Friendly Version
05/02/17Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Five Nordic CountriesPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.